SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – ...

Related Keywords

United States ,American ,Samantha Hilson Sandler ,Saqib Islam ,European Medicines Agency ,Nasdaq ,American Society Of Clinical Oncology ,Linkedin ,Youtube ,Drug Administration ,Trademark Office ,Springworks Therapeutics Inc ,Development Rd Expenses ,Beigene Ltd ,Twitter ,European Union ,Works Therapeutics ,Chief Executive Officer ,Business Highlights ,Supplemental New Drug Application ,Marketing Authorization Application ,Clinical Oncology ,Springworks Sponsored Phase ,Epidermal Growth Factor Receptor ,Beigene Sponsored Phase ,Loss Attributable ,Common Stockholders ,Cash Equivalents ,Marketable Securities ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Consolidated Statements ,Markets ,